Article
A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Journal of neurochemistry - 1 Dec 2011
Onishi Tomohiro, Iwashita Hiroki, Uno Yumiko, Kunitomo Jun, Saitoh Morihisa, Kimura Eiji, Fujita Hisashi, Uchiyama Noriko, Kori Masakuni, Takizawa Masayuki
Abstract excerpt
Alzheimer's disease (AD) is a neurodegenerative disorder leading to a progressive loss of cognitive function and is pathologically characterized by senile plaques and neurofibrillary tangles. Glycogen synthase kinase-3 (GSK-3) is involved in AD pathogenesis. GSK-3 is reported not only to phosphorylate tau, a major component of neurofibrillary tangles, but also to regulate the production of amyloid β, which is...
Topics
- Alzheimer Disease
- Amyloid beta-Peptides
- Amyloid beta-Protein Precursor
- Animals
- Benzofurans
- Brain
- Cell Culture Techniques
- Cerebral Cortex
- Cognition Disorders